相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Transthyretin cardiac amyloidosis: A treatable form of heart failure with a preserved ejection fraction
Jan M. Griffin et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2021)
Multidisciplinary Approaches for Transthyretin Amyloidosis
Haruki Koike et al.
CARDIOLOGY AND THERAPY (2021)
Two distinct mechanisms of neuropathy in immunoglobulin light chain (AL) amyloidosis
Haruki Koike et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2021)
Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis
Jan M. Griffin et al.
CIRCULATION RESEARCH (2021)
A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells
Aubin Michalon et al.
NATURE COMMUNICATIONS (2021)
Inotersen therapy of transthyretin amyloid cardiomyopathy
Noel R. Dasgupta et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2020)
Cellular secretion and cytotoxicity of transthyretin mutant proteins underlie late-onset amyloidosis and neurodegeneration
Ridwan Babatunde Ibrahim et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2020)
A novel monoclonal antibody targeting aggregated transthyretin facilitates its removal and functional recovery in an experimental model
Jacob George et al.
EUROPEAN HEART JOURNAL (2020)
Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment
Morie A. Gertz
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Acquired and inherited amyloidosis: Knowledge driving patients' care
Laura Obici et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2020)
Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial
Anita D'Souza et al.
ECLINICALMEDICINE (2020)
Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee
Merrill D. Benson et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2020)
Transthyretin Amyloidosis: Update on the Clinical Spectrum, Pathogenesis, and Disease-Modifying Therapies
Haruki Koike et al.
NEUROLOGY AND THERAPY (2020)
Treatment of cardiac transthyretin amyloidosis: an update
Michele Emdin et al.
EUROPEAN HEART JOURNAL (2019)
Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease
David Adams et al.
NATURE REVIEWS NEUROLOGY (2019)
Clinical Experience With the Use of Doxycycline and Ursodeoxycholic Acid for the Treatment of Transthyretin Cardiac Amyloidosis
Erin Karlstedt et al.
JOURNAL OF CARDIAC FAILURE (2019)
Clinicopathological spectrum and recent advances in the treatment of hereditary transthyretin amyloidosis
Haruki Koike et al.
NEUROLOGY AND CLINICAL NEUROSCIENCE (2019)
Ultrastructure in Transthyretin Amyloidosis: From Pathophysiology to Therapeutic Insights
Haruki Koike et al.
BIOMEDICINES (2019)
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
D. Adams et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
M. D. Benson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The morphology of amyloid fibrils and their impact on tissue damage in hereditary transthyretin amyloidosis: An ultrastructural study
Haruki Koike et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2018)
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Mathew S. Maurer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cellular clearance of circulating transthyretin decreases cell-nonautonomous proteotoxicity in Caenorhabditis elegans
Kayalvizhi Madhivanan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
First nationwide survey on systemic wild-type ATTR amyloidosis in Japan
Yoshiki Sekijima et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2018)
Novel Antibody for the Treatment of Transthyretin Amyloidosis
Akihiko Hosoi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction
Morie A. Gertz et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Systemic amyloidosis
Ashutosh D. Wechalekar et al.
LANCET (2016)
Schwann cell and endothelial cell damage in transthyretin familial amyloid polyneuropathy
Haruki Koike et al.
NEUROLOGY (2016)
Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction
Esther Gonzalez-Lopez et al.
EUROPEAN HEART JOURNAL (2015)
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component
Duncan B. Richards et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The amyloid state and its association with protein misfolding diseases
Tuomas P. J. Knowles et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Repurposing Diflunisal for Familial Amyloid Polyneuropathy A Randomized Clinical Trial
John L. Berk et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Pro-oxidative effects of aggregated transthyretin in human Schwannoma cells
Vai Hong Fong et al.
NEUROTOXICOLOGY (2013)
Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study
Laura Obici et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2012)
Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas
Haruki Koike et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)
Tafamidis for transthyretin familial amyloid polyneuropathy A randomized, controlled trial
Teresa Coelho et al.
NEUROLOGY (2012)
Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis
Haruki Koike et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2011)
Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study
Mitsuharu Ueda et al.
MODERN PATHOLOGY (2011)
Radioimmunodetection of amyloid deposits in patients with AL amyloidosis
Jonathan S. Wall et al.
BLOOD (2010)
Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30)
Gösta Holmgren et al.
CLINICAL GENETICS (2010)
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits
Karl Bodin et al.
NATURE (2010)
Protein aggregation diseases: pathogenicity and therapeutic perspectives
Adriano Aguzzi et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Chain reaction of amyloid fibril formation with induction of basement membrane in familial amyloidotic polyneuropathy
Yohei Misumi et al.
JOURNAL OF PATHOLOGY (2009)
Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy
Haruki Koike et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2009)
Cholesterol and anionic phospholipids increase the binding of amyloidogenic transthyretin to lipid membranes
Xu Hou et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2008)
Matrix Metalloproteinases and Their Tissue Inhibitors in Cardiac Amyloidosis Relationship to Structural, Functional Myocardial Changes and to Light Chain Amyloid Deposition
Andreia Biolo et al.
CIRCULATION-HEART FAILURE (2008)
Activation of ERK1/2 MAP kinases in familial amyloidotic polyneuropathy
FA Monteiro et al.
JOURNAL OF NEUROCHEMISTRY (2006)
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
MA Gertz et al.
AMERICAN JOURNAL OF HEMATOLOGY (2005)
Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy
H Koike et al.
NEUROLOGY (2004)
Up-regulation of the extracellular matrix remodeling genes, biglycan, neutrophil gelatinase-associated lipocalin and matrix metalloproteinase-9 in familial amyloid polyneuropathy
MM Sousa et al.
FASEB JOURNAL (2004)
Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan - Early-vs late-onset form
H Koike et al.
ARCHIVES OF NEUROLOGY (2002)
分享论文
